Related Experiment Video

Updated: Apr 16, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL

Thomas Trimarchi1, Iannis Aifantis1

  • 1Department of Pathology and Howard Hughes Medical Institute, NYU School of Medicine New York, NY 10016, USA.

Cancer Cell
|March 12, 2015
PubMed

Insights

Treatment for relapsed aggressive pre-B acute lymphoblastic leukemia (ALL) is challenging. This study surveys pre-B cell receptor activation and downstream signaling for targeted therapies.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Pre-B acute lymphoblastic leukemia (ALL) is an aggressive blood cancer.
  • Relapsed and refractory disease present significant treatment challenges.

Purpose of the Study:

  • To survey the activation status of the pre-B cell receptor (pre-BCR) in pre-B ALL.
  • To investigate downstream signaling mechanisms actionable with small molecule inhibitors.

Main Methods:

  • Survey of pre-B cell receptor activation status.
  • Comprehensive investigation of downstream signaling pathways.

Main Results:

  • Detailed analysis of pre-BCR signaling pathways.
  • Identification of targetable mechanisms for small molecule inhibitors.

Conclusions:

  • Understanding pre-BCR signaling is crucial for developing new therapies.
  • Targeting these pathways may overcome treatment resistance in pre-B ALL.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

698

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72